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oxide has made its use somewhat prohibitive. In this report,
we demonstrate the technique of using inhaled prostacyclin in
patients with reperfusion injury. We have also identified some
potential advantages of inhaled prostacyclin over inhaled
nitric oxide.
In this patient, inhaled prostacyclin was effective at
decreasing the elevated pulmonary artery pressures associated
with reperfusion injury. We and others believe decreasing pul-
monary artery pressure lessens water accumulation and injury
to the transplanted lung.3 To our knowledge, no other authors
have reported on the clinical use of inhaled prostacyclin for
the treatment of lung transplant reperfusion injury. Some clin-
ical studies, however, have investigated the effect of inhaled
prostacyclin on acute respiratory distress syndrome.4,5 Van
Heerden and associates4 demonstrated effective use of inhaled
prostacyclin in 9 patients with acute respiratory distress syn-
drome. Those authors demonstrated a significant dose-depen-
dent improvement in arterial oxygenation/percent inhaled
oxygen ratio after administration of inhaled prostacyclin. No
significant complications resulted from the use of the drug. 
Some animal studies have demonstrated the beneficial
effects of intravenous prostacyclin in reducing lung transplant
reperfusion injury.6,7 Matsuzaki and colleagues6 demonstrated
reduced reperfusion injury in a rabbit model after intravenous
prostacyclin. Okada and coworkers7 similarly demonstrated
reduced reperfusion injury in a rat model after the administra-
tion of intravenous prostacyclin. Although these investiga-
tions show improvement in lung reperfusion injury after the
administration of intravenous prostacyclin, to our knowledge
only one animal study has shown an improvement in reperfu-
sion injury after the administration of inhaled prostacyclin.3
Treatment options for patients with severe reperfusion
injury after lung transplantation often include the use of
inhaled nitric oxide. However, the recent escalation in cost has
made its use somewhat prohibitive. Here we describe the tech-
nique of using inhaled prostacyclin (epoprostenol), as op-
posed to using inhaled nitric oxide, for the treatment of lung
transplant reperfusion injury. We believe this is the first
reported case of its use in this setting.
Clinical summary. A 51-year-old man underwent single
lung transplantation for chronic obstructive pulmonary dis-
ease. Severe reperfusion injury subsequently developed, with
an oxygenation index of greater than 30.1 The chest radi-
ograph showed almost complete white-out of the transplanted
lung. Mean pulmonary artery pressures preoperatively were
24 mm Hg. Mean pulmonary artery pressures after lung trans-
plantation were 35 to 40 mm Hg. This patient was subse-
quently treated by arteriovenous extracorporeal membrane
oxygenation (ECMO). After the start of ECMO, mean pul-
monary artery pressures remained at 35 to 40 mm Hg. Given
this, we were concerned that the patient had ongoing reperfu-
sion injury. We and others have thought that pulmonary
vasodilators, such as inhaled nitric oxide, help to decrease
reperfusion injury by decreasing pulmonary vascular resis-
tance and increasing pulmonary artery blood flow.2 However,
given the substantial cost of inhaled nitric oxide, we instead
chose to administer inhaled, aerosolized prostacyclin at a rate
of 50 ng · kg–1 · min–1 using an in-line circuit and MiniHeart
nebulizer chamber (Vortran Medical Technology, Inc,
Sacramento, Calif) (Table I). After institution of aerosolized
prostacyclin, mean pulmonary artery pressures dropped to 25
to 30 mm Hg. After 48 hours the patient was weaned from
ECMO and continued receiving inhaled prostacyclin for an
additional 24 hours. This patient eventually recovered and
was discharged to his home on hospital day 11.
Comment. Nitric oxide has often been used as an adjunc-
tive measure for the treatment of reperfusion injury with some
success.2 However, the recent cost increase in inhaled nitric
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Table I.  Aerosolized prostacyclin protocol for lung
transplant recipients
1 Lung transplant patients with elevated pulmonary artery pressures
(mean pulmonary artery pressure > 20 mm Hg or pulmonary vas-
cular resistance > 200 dynes · s · cm–5) and a low cardiac index
(cardiac index < 2.5 L · min–1 ·m–2) owing to right heart failure
2 Patients with right heart failure owing to left heart failure are
excluded
3 Initial dose of inhaled epoprostenol is 50 ng · kg–1 · min–1
4 If the initial dose causes a decrease in systemic blood pressure by
more than 10%, the rate is decreased to 25 ng · kg–1 · min–1
5 The initial dose is cut in half every 15 minutes to find the lowest
effective dose
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One advantage of inhaled prostacyclin is that it avoids the
possible buildup of oxygen radicals associated with inhaled
nitric oxide. Some authors have questioned whether or not
a toxic buildup of oxygen radicals occurs with the use of
nitric oxide.8,9 Murakami and coworkers8 demonstrated
improvement in reperfusion injury after administration of
nitric oxide at low doses, although higher doses seemed to
worsen reperfusion injury. Eppinger and coworkers9 found
similar results.
Another advantage of inhaled prostacyclin is that it is also
less expensive than inhaled nitric oxide. Patient charges at our
institution for inhaled nitric oxide are $5500 a day regardless
of amount used. In comparison, inhaled prostacyclin costs
$960 a day at a dosage of 50 ng · kg–1 · min–1, which is the
recommended maximal clinical dosage. 
In summary, inhaled prostacyclin appeared to be as effec-
tive as inhaled nitric oxide, may have the advantage of avoid-
ing the potential buildup of oxygen radicals, and is cheaper
than nitric oxide. Thus, inhaled prostacyclin should be con-
sidered in patients with severe reperfusion injury after lung
transplantation.
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